Latest News

Largest real-world dataset reports on deferred revascularisation in stable angina and ACS
Written by: ACIST
Head-to-Head Study Validates Consistent Performance of Microcatheter FFR
Written by: BIOTRONIK
EuroPCR 2017: Magmaris Resorbable Scaffold Shows Low Scaffold Thrombosis Risk
NEW STUDY SHOWS DELAYED USE OF BLOOD THINNERS FOR ATRIAL FIBRILLATION INCREASES RISK OF DEMENTIA
LONG-TERM RESULTS SHOW WIRELESS DEVICE IS EFFECTIVE FOR HEART FAILURE PATIENTS
ARTIFICIAL INTELLIGENCE AUTOMATICALLY DETECTS ATRIAL FIBRILLATION USING APPLE WATCH’S HEART RATE SENSOR
WEARABLE CARDIOVERTER DEFIBRILLATORS PROVE TO BE SAFE FOR PEDIATRIC PATIENTS AT RISK FOR SUDDEN CARDIAC…
Written by: BRIEF-Abbott reports
BRIEF-Abbott reports CE Mark for tacticath contact force ablation catheter
Written by: Abbott
Abbott Announces CE Mark for TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ New: Cardiac…
Risk of heart transplant rejection reduced by desensitising patient antibodies

External news

Written by: Cardiac Vascular News
HELP Therapeutics announces FDA clearance of IND application for universal iPSC-derived HiCM-188 cell therapy for the treatment of end-stage heart failure
Written by: Cardiac Vascular News
Okami Medical Announces Closing Of $32.5M Financing
Written by: Cardiac Vascular News
Arineta Expands Cardiac Care in Georgia with Installation of Advanced SpotLight™ Duo Scanner at PACE
Written by: Cardiovascular Business
Key steps to implementing a successful PET program
Written by: Cardiovascular Business
New Category I CPT codes announced for treating heart failure with implantable Barostim device
Written by: Medscape
The Genitals Are a Window Into Health: Sex as a Vital Sign
Written by: Cardiac Vascular News
Provident Healthcare Partners Advises Birmingham Heart Clinic in its Partnership with U.S. Heart & Vascular
Written by: Cardiac Vascular News
Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation
Written by: Medscape
ASA Releases New Primary Stroke Prevention Guideline
Written by: Cardiac Vascular News
Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial